Skip to main content
SpringerLink
Log in
Book cover

Albert and Jakobiec's Principles and Practice of Ophthalmology pp 2935–2953Cite as

Epidemiology and Genetics of Diabetic Retinopathy

  • Reference work entry
  • First Online:

  • 72 Accesses

Abstract

Diabetic retinopathy (DR) is a potentially blinding microvascular complication of type 1 and type 2 diabetes that affect individuals around the world. Global estimates predict that the number of individuals with DR will continue increasing over the next decade. Regional, national, and multinational studies have followed up populations to gain insight into the epidemiology of diabetic retinopathy. Other studies have been conducted in an attempt to understand the risk factors for DR. Literature on DR has found that the strongest predictor of DR is the duration of diabetes and hyperglycemia. Other factors that potentially play a role in DR include blood pressure, impaired renal function, hyperlipidemia, demographics, pregnancy, socioeconomic status, genetics, and body mass index. Understanding the definition, diagnosis, incidence, prevalence, and risk factors for the disease is important for optimal patient management. This chapter summarizes the findings of publications regarding the epidemiology and risk factors associated with DR.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   5,499.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   6,499.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. The eye diseases prevalence research G. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004a;122(4):477–85.

    Article  Google Scholar 

  2. Federation ID. IDF diabetes atlas. Brussels: International Diabetes Federation; 2017.

    Google Scholar 

  3. Kourgialis N. Diabetic retinopathy – silently blinding millions of people world-wide. IAPB Vision Atlas [cited 2019 1/7/19]. Available from: http://atlas.iapb.org/vision-trends/diabetic-retinopathy/.

  4. Leasher JL, Bourne RR, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, et al. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010. Diabetes Care. 2016;39(9):1643–9.

    Article  PubMed  Google Scholar 

  5. Atlas ID. International Diabetes Federation, 2013. ISBN 2930229853. 2015;7.

    Google Scholar 

  6. The Eye Diseases Prevalence Research G. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122(4):552–63.

    Article  Google Scholar 

  7. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology. 1984;91(1):1–9.

    Article  CAS  PubMed  Google Scholar 

  8. Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS report number 12: ETDRS report number 12. Ophthalmology 1991;98(5):823–833.

    Google Scholar 

  9. Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the diabetic retinopathy. Invest Ophthalmol Vis Sci. 1981;21(1 Pt 2):1–226.

    Google Scholar 

  10. Fukuda M. Clinical arrangement of classification of diabetic retinopathy. Tohoku J Exp Med. 1983;141(Suppl):331.

    Article  PubMed  Google Scholar 

  11. Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677–82.

    Article  CAS  PubMed  Google Scholar 

  12. Zhang X, Saaddine JB, Chou C-F, Cotch MF, Cheng YJ, Geiss LS, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA. 2010;304(6):649–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Regillo CD, Callanan DG, Do DV, Fine HF, Holekamp NM, Kuppermann BD, et al. Use of corticosteroids in the treatment of patients with diabetic macular edema who have a suboptimal response to anti-VEGF: recommendations of an expert panel. Ophthalmic Surg Lasers Imaging Retina. 2017;48(4):291–301.

    Article  PubMed  Google Scholar 

  14. Four risk factors for severe visual loss in diabetic retinopathy: the third report from the diabetic retinopathy study. Arch Ophthalmol. 1979;97(4):654–655.

    Google Scholar 

  15. Roy MS, Klein R, O’Colmain BJ, Klein BEK, Moss SE, Kempen JH. The prevalence of diabetic retinopathy among adult type1 diabetic persons in the United States. Arch Ophthalmol. 2004;122(4):546–51.

    Article  PubMed  Google Scholar 

  16. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; DC_111909

    Google Scholar 

  17. Klein R, Klein BE, Moss SE, Davis MD, Demets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol (Chicago, Ill : 1960). 1989a;107(2):237.

    Article  CAS  Google Scholar 

  18. Klein R, Klein BK, Moss SE, Cruickshanks KJ. The Wisconsin epidemiologic study of diabetic retinopathy: Xiv. ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol. 1994;112(9):1217–28.

    Article  CAS  PubMed  Google Scholar 

  19. Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin epidemiologic study of diabetic retinopathy: XVII: the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes 1 1 proprietary interest: none. Ophthalmology. 1998;105(10):1801–15.

    Article  CAS  PubMed  Google Scholar 

  20. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BEK. The Wisconsin epidemiologic study of diabetic retinopathy XXII: the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115(11):1859–68.

    Article  PubMed  Google Scholar 

  21. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy: X. four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. JAMA Ophthalmol. 1989b;107(2):244–9.

    CAS  Google Scholar 

  22. Krolewski AS, Warram JH, Rand LI, Christlieb AR, Busick EJ, Kahn CR. Risk of proliferative diabetic retinopathy in juvenile-onset type I diabetes: a 40-yr follow-up study. Diabetes Care. 1986;9(5):443.

    Article  CAS  PubMed  Google Scholar 

  23. Haffner SM, Fong D, Stern MP, Pugh JA, Hazuda HP, Patterson JK, et al. Diabetic retinopathy in Mexican Americans and non-Hispanic whites. Diabetes. 1988;37(7):878.

    Article  CAS  PubMed  Google Scholar 

  24. Liu Y, Wang M, Morris AD, Doney ASF, Leese GP, Pearson ER, et al. Glycemic exposure and blood pressure influencing progression and remission of diabetic retinopathy: a longitudinal cohort study in GoDARTS. Diabetes Care. 2013;36(12):3979–84.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Xu J, Xu L, Wang YX, You QS, Jonas JB, Wei WB. Ten-year cumulative incidence of diabetic retinopathy. The Beijing Eye Study 2001/2011. PLoS One. 2014;9(10):e111320.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Kajiwara A, Miyagawa H, Saruwatari J, Kita A, Sakata M, Kawata Y, et al. Gender differences in the incidence and progression of diabetic retinopathy among Japanese patients with type 2 diabetes mellitus: A clinic-based retrospective longitudinal study. Diabetes Res Clin Pract. 2014;103(3):e7–e10.

    Article  CAS  PubMed  Google Scholar 

  27. Klein R, Klein BEK, Moss SE, Davis MD, Demets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA. 1988;260(19):2864–71.

    Article  CAS  PubMed  Google Scholar 

  28. Kostraba J, Klein R, Dorman J, Becker D, Drash A, Maser R, et al. The epidemiology of diabetes complications study. IV. Correlates of diabetic background and proliferative retinopathy. Am J Epidemiol. 1991;133(4):381.

    Article  CAS  PubMed  Google Scholar 

  29. D’Antonio JA, Ellis D, Doft BH, Becker DJ, Drash AL, Kuller LH, et al. Diabetes complications and glycemic control. The Pittsburgh prospective insulin-dependent diabetes cohort study status report after 5 yr of IDDM. Diabetes Care. 1989;12(10):694.

    Google Scholar 

  30. Penman A, Hoadley S, Wilson JG, Taylor HA, Chen CJ, Sobrin L. P-selectin plasma levels and genetic variant associated with diabetic retinopathy in African Americans. Am J Ophthalmol. 2015, 159(6):1152–60.e2.

    Google Scholar 

  31. Intine RV, Olsen AS, Sarras MP Jr. A zebrafish model of diabetes mellitus and metabolic memory. J Vis Exp. 2013;2013(72):e50232.

    Google Scholar 

  32. Doczi-Keresztesi Z, Jung J, Kiss I, Mezei T, Szabo L, Ember I. Retinal and renal vascular permeability changes caused by stem cell stimulation in alloxan-induced diabetic rats, measured by extravasation of fluorescein. in vivo. 2012;26(3):427–35.

    CAS  PubMed  Google Scholar 

  33. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.

    Article  Google Scholar 

  34. Lachin JM, Genuth S, Cleary P, Davis MD, Nathan DM. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342(6):381–9.

    Article  PubMed  Google Scholar 

  35. The Writing Team for the Diabetes C, Complications Trial/Epidemiology of Diabetes I, Complications Research G. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287(19):2563–9.

    Article  Google Scholar 

  36. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.

    Article  CAS  PubMed  Google Scholar 

  37. White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol (Chicago, Ill : 1960). 2008;126(12):1707–15.

    Article  Google Scholar 

  38. Diabetes C, Complications Trial /Epidemiology of Diabetes I, Complications Research G, Lachin JM, White NH, Hainsworth DP, et al. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes. 2015;64(2):631–42.

    Article  CAS  Google Scholar 

  39. Turner R, Holman R, Cull C, Stratton I. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998a;352(9131):837–53.

    Article  Google Scholar 

  40. Group AS, Group AES, Chew EY, Ambrosius WT, Davis MD, Danis RP, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233–44.

    Article  CAS  Google Scholar 

  41. Persistent effects of intensive glycemic control on retinopathy in Type 2 diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) follow-on study. Diabetes Care. 2016;39(7):1089–100.

    Google Scholar 

  42. Association AD. Standards of Medical Care in Diabetes – 2019. Diabetes Care 2019. 2019;42(Suppl. 1)

    Google Scholar 

  43. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BEK. The Wisconsin epidemiologic study of diabetic retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116(3):497–503.

    Article  PubMed  Google Scholar 

  44. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995 Jan;102(1):7–16.

    Article  CAS  PubMed  Google Scholar 

  45. Turner R, Holman R, Stratton I, Cull C. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. (United Kingdom Prospective Diabetes Study Group). Br Med J. 1998b;317(7160):703.

    Article  Google Scholar 

  46. Holman R, Turner R, Stratton I, Cull C. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J. 1998;317(7160):713–20.

    Article  Google Scholar 

  47. Beulens JWJ, Patel A, Vingerling JR, Cruickshank JK, Hughes AD, Stanton A, et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia. 2009;52(10):2027–36.

    Article  CAS  PubMed  Google Scholar 

  48. Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, et al. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev. 2015;1:CD006127.

    PubMed  Google Scholar 

  49. Chaturvedi N, Sjolie A-K, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet. 1998;351(9095):28–31.

    Article  CAS  PubMed  Google Scholar 

  50. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, et al. Renal and retinal effects of enalapril and losartan in type 1 Diabetes. N Engl J Med. 2009;361(1):40–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008;372(9647):1385–93.

    Article  CAS  PubMed  Google Scholar 

  52. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;372(9647):1394–402.

    Article  CAS  PubMed  Google Scholar 

  53. Sjölie AK, Chaturverdi N, Fuller J. Effekt af lisinopril på progression af retinopati og mikroalbuminuri hos normotensive personer med insulinafhaengig diabetes mellitus. Ugeskr Laeger. 1999;161(7)

    Google Scholar 

  54. Michael C, Emily YC, Byron H, Elvira A, Lieling W, Anna L, et al. Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26. Kidney Int. 2004;66(3):1173.

    Article  Google Scholar 

  55. Group TMCS. Predictors of the development of microalbuminuria in patients with type 1 diabetes mellitus: a seven-year prospective study. Diabet Med. 1999;16(11):918–25.

    Article  Google Scholar 

  56. Klein R, Klein B, Moss S, Davis M, DeMets D. Retinopathy WESoD. V. Proteinuria and retinopathy in a population of diabetic persons diagnosed prior to 30 years of age. Diabet Renal-Retinal Syndr. 1986;3:245–64.

    Google Scholar 

  57. Lee WJ, Sobrin L, Lee MJ, Kang MH, Seong M, Cho H. The relationship between diabetic retinopathy and diabetic nephropathy in a population-based study in Korea (KNHANES V-2, 3) relationship between DR and DN in Korea. Invest Ophthalmol Vis Sci. 2014;55(10):6547–53.

    Article  CAS  PubMed  Google Scholar 

  58. Mathiesen ER, Rønn B, Storm B, Foght H, Deckert T. The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study. Diabet Med. 1995;12(6):482–7.

    Article  CAS  PubMed  Google Scholar 

  59. Estacio R, McFarling E, Biggerstaff S, Jeffers B, Johnson D, Schrier RW. Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM. Am J Kidney Dis. 1998;31(6):947–53.

    Article  CAS  PubMed  Google Scholar 

  60. Pradhan R, Fong D, March C, Jack R, Rezapour G, Norris K, et al. Angiotensin-converting enzyme inhibition for the treatment of moderate to severe diabetic retinopathy in normotensive type 2 diabetic patients: a pilot study. J Diabetes Complicat. 2002;16(6):377–81.

    Article  Google Scholar 

  61. Wang B, Wang F, Zhang Y, Zhao S-H, Zhao W-J, Yan S-L, et al. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(4):263–74.

    Article  CAS  PubMed  Google Scholar 

  62. Chew EY, Klein ML, Ferris FL, Remaley NA, Murphy RP, Chantry K, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: Early Treatment Diabetic Retinopathy Study (ETDRS) report 22. Arch Ophthalmol. 1996;114(9):1079–84.

    Article  CAS  PubMed  Google Scholar 

  63. Sasaki M, Kawasaki R, Noonan JE, Wong TY, Lamoureux E, Wang JJ. Quantitative measurement of hard exudates in patients with diabetes and their associations with serum lipid levels. Invest Ophthalmol Vis Sci. 2013;54(8):5544–50.

    Article  CAS  PubMed  Google Scholar 

  64. Idiculla J, Nithyanandam S, Joseph M, Mohan VA, Vasu U, Sadiq M. Serum lipids and diabetic retinopathy: a cross-sectional study. Indian J Endocrinol Metab. 2012;16(Suppl 2):S492–S4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Benarous R, Sasongko MB, Qureshi S, Fenwick E, Dirani M, Wong TY, et al. Differential association of serum lipids with diabetic retinopathy and diabetic macular edema. Invest Ophthalmol Vis Sci. 2011;52(10):7464–9.

    Article  CAS  PubMed  Google Scholar 

  66. Raman R, Rani PK, Kulothungan V, Reddi Rachepalle S, Kumaramanickavel G, Sharma T. Influence of serum lipids on clinically significant versus nonclinically significant macular edema: SN-DREAMS report number 13. Ophthalmology. 2010;117(4):766–72.

    Article  PubMed  Google Scholar 

  67. Sasaki M, Kawashima M, Kawasaki R, Uchida A, Koto T, Shinoda H, et al. Association of serum lipids with macular thickness and volume in type 2 diabetes without diabetic macular edema lipids related to CSMT and CSMV in diabetes without DME. Invest Ophthalmol Vis Sci. 2014;55(3):1749–53.

    Article  CAS  PubMed  Google Scholar 

  68. Davoudi S, Papavasileiou E, Roohipoor R, Cho H, Kudrimoti S, Hancock H, et al. Optical coherence tomography characteristics of macular edema and hard exudates and their association with lipid serum levels in type 2 diabetes. Retina. 2016;36(9):1622–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Klein BEK, Moss SE, Klein R, Surawicz TS. The Wisconsin epidemiologic study of diabetic retinopathy: XIII. Relationship of serum cholesterol to retinopathy and hard exudate: XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology. 1991;98(8):1261–5.

    Article  CAS  PubMed  Google Scholar 

  70. Papavasileiou E, Davoudi S, Roohipoor R, Cho H, Kudrimoti S, Hancock H, et al. Association of serum lipid levels with retinal hard exudate area in African Americans with type 2 diabetes. Graefes Arch Clin Exp Ophthalmol. 2017;255(3):509–17.

    Article  CAS  PubMed  Google Scholar 

  71. Klein R, Sharrett AR, Klein BEK, Moss SE, Folsom AR, Wong TY, et al. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study. Ophthalmology. 2002;109(7):1225–34.

    Article  PubMed  Google Scholar 

  72. Sachdev N, Sahni A. Association of systemic risk factors with the severity of retinal hard exudates in a north Indian population with type 2 diabetes. J Postgrad Med. 2010;56(1):3.

    Article  CAS  PubMed  Google Scholar 

  73. Keech AC, Mitchell P, Summanen PA, O’Day J, Davis TME, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370(9600):1687–97.

    Article  CAS  PubMed  Google Scholar 

  74. Sobrin L, Chong YH, Fan Q, Gan A, Stanwyck LK, Kaidonis G, et al. Genetically determined plasma lipid levels and risk of diabetic retinopathy: a Mendelian randomization study. Diabetes. 2017;66(12):3130.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Chew EY, Ambrosius WT. Update of the ACCORD eye study. N Engl J Med. 2011;364(2):188–9.

    Article  CAS  PubMed  Google Scholar 

  76. Kang EY-C, Chen T-H, Garg SJ, Sun C-C, Kang J-H, Wu W-C, et al. Association of statin therapy with prevention of vision-threatening diabetic retinopathy. JAMA Ophthalmol. 2019;137(4):363–71.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Nielsen SF, Nordestgaard BG. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. Lancet Diabetes Endocrinol. 2014;2(11):894–900.

    Article  CAS  PubMed  Google Scholar 

  78. Sun JK, Keenan HA, Cavallerano JD, Asztalos BF, Schaefer EJ, Sell DR, et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the Joslin 50-year medalist study. Diabetes Care. 2011;34(4):968–74.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Varma R, Macias GL, Torres M, Klein R, Peña FY, Azen SP. Biologic risk factors associated with diabetic retinopathy: the Los Angeles Latino eye study. Ophthalmology. 2007;114(7):1332–40.

    Article  PubMed  Google Scholar 

  80. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44(2):156–63.

    Article  CAS  PubMed  Google Scholar 

  81. Varma R, Torres M, Peña F, Klein R, Azen SP. Prevalence of diabetic retinopathy in adult Latinos: the Los Angeles Latino eye study. Ophthalmology. 2004;111(7):1298–306.

    Article  PubMed  Google Scholar 

  82. Roy MS, Affouf M. Six-year progression of retinopathy and associated risk factors in African American patients with type 1 diabetes mellitus: the New Jersey 725. JAMA Ophthalmol. 2006;124(9):1297–306.

    Google Scholar 

  83. Wong TY, Klein R, Islam FMA, Cotch MF, Folsom AR, Klein BEK, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol. 2006;141(3):446–55.e1.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Leske MC, Wu S-Y, Hennis A, Nemesure B, Schachat AP, Hyman L, et al. Nine-year incidence of diabetic retinopathy in the Barbados eye studies. Arch Ophthalmol. 2006;124(2):250–5.

    Article  PubMed  Google Scholar 

  85. Emanuele N, Sacks J, Klein R, Reda D, Anderson R, Duckworth W, et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care. 2005;28(8):1954–8.

    Article  PubMed  Google Scholar 

  86. Gao X, Gauderman WJ, Marjoram P, Torres M, Chen Y-DI, Taylor KD, et al. Native American ancestry is associated with severe diabetic retinopathy in Latinos genetic ancestry and severe DR in Latinos. Invest Ophthalmol Vis Sci. 2014;55(9):6041–5.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Varma R, Bressler NM, Doan QV, Gleeson M, Danese M, Bower JK, et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132(11):1334–40.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Vestgaard M, Ringholm L, Laugesen CS, Rasmussen KL, Damm P, Mathiesen ER. Pregnancy-induced sight-threatening diabetic retinopathy in women with type 1 diabetes. Diabet Med. 2010;27(4):431–5.

    Article  CAS  PubMed  Google Scholar 

  89. Rasmussen KL, Laugesen CS, Ringholm L, Vestgaard M, Damm P, Mathiesen ER. Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes. Diabetologia. [journal article]. 2010;53(6):1076–1083.

    Google Scholar 

  90. Chew EY, Mills JL, Metzger BE, Remaley NA, Jovanovic-Peterson L, Knopp RH, et al. Metabolic control and progression of retinopathy. The diabetes in early pregnancy study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Diabetes Care. 1995;18(5):631.

    Article  CAS  PubMed  Google Scholar 

  91. Rodman H, Singerman L, Aiello L. In: Merkatz TR, PAJ A, editors. Diabetic retinopathy and its relation to pregnancy. The diabetic pregnancy and perinatal perspective. New York: Grune and Stratton; 1979.

    Google Scholar 

  92. Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care. 1990;13(1):34.

    Article  CAS  PubMed  Google Scholar 

  93. Diabetes C. Complications trial research G. effect of pregnancy on microvascular complications in the diabetes control and complications trial. The diabetes control and complications trial research group. Diabetes Care. 2000;23(8):1084–91.

    Article  Google Scholar 

  94. Phelps RL, Sakol P, Metzger BE, Jampol LM, Freinkel N. Changes in diabetic retinopathy during pregnancy correlations with regulation of hyperglycemia. Arch Ophthalmol. 1986;104(12):1806–10.

    Article  CAS  PubMed  Google Scholar 

  95. Gunderson EP, Lewis CE, Tsai A-L, Chiang V, Carnethon M, Quesenberry CP, et al. A 20-year prospective study of childbearing and incidence of diabetes in young women, controlling for Glycemia before conception. Coron Artery Risk Dev Young Adults (CARDIA) Study. 2007;56(12):2990–6.

    CAS  Google Scholar 

  96. Hanna AK, Roy M, Zinman B, McCulloch JC, Mortimer C, Falk JA, et al. An evaluation of factors associated with proliferative diabetic retinopathy. Clin Invest Med. 1985;8(2):109.

    CAS  PubMed  Google Scholar 

  97. Scanlon PH, Carter SC, Foy C, Husband RFA, Abbas J, Bachmann MO. Diabetic retinopathy and socioeconomic deprivation in Gloucestershire. J Med Screen. 2008;15(3):118–21.

    Article  CAS  PubMed  Google Scholar 

  98. Low L, Law JP, Hodson J, McAlpine R, O’Colmain U, MacEwen C. Impact of socioeconomic deprivation on the development of diabetic retinopathy: a population-based, cross-sectional and longitudinal study over 12 years. BMJ Open. 2015;5(4):e007290.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Emoto N, Okajima F, Sugihara H, Goto R. A socioeconomic and behavioral survey of patients with difficult-to-control type 2 diabetes mellitus reveals an association between diabetic retinopathy and educational attainment. Patient Prefer Adherence. 2016;10:2151–62.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Kaštelan S, Tomić M, Gverović Antunica A, Ljubić S, Salopek Rabatić J, Karabatić M. Body mass index: a risk factor for retinopathy in type 2 diabetic patients. Mediat Inflamm. 2013;2013:436329.

    Google Scholar 

  101. Zhou Y, Zhang Y, Shi K, Wang C. Body mass index and risk of diabetic retinopathy: A meta-analysis and systematic review. Medicine (Baltimore). 2017;96(22):e6754.

    Article  Google Scholar 

  102. Klein R, Klein BK, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy: Ii. prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984b;102(4):520–6.

    Article  CAS  PubMed  Google Scholar 

  103. Lim LS, Tai ES, Mitchell P, Wang JJ, Tay WT, Lamoureux E, et al. C-reactive protein, body mass index, and diabetic retinopathy. Invest Ophthalmol Vis Sci. 2010;51(9):4458–63.

    Article  PubMed  Google Scholar 

  104. Klein R, Klein BEK, Moss SE. Is obesity related to microvascular and macrovascular complications in diabetes?: The Wisconsin epidemiologic study of diabetic retinopathy. JAMA Intern Med. 1997;157(6):650–6.

    Article  CAS  Google Scholar 

  105. Chan JCY, Chee ML, Tan NYQ, Cheng C-Y, Wong TY, Sabanayagam C. Differential effect of body mass index on the incidence of diabetes and diabetic retinopathy in two Asian populations. Nutr Diabetes. 2018;8(1):16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Zhu W, Wu Y, Meng Y-F, Xing Q, Tao J-J, Lu J. Association of obesity and risk of diabetic retinopathy in diabetes patients: a meta-analysis of prospective cohort studies. Medicine (Baltimore). 2018;97(32):e11807.

    Article  Google Scholar 

  107. The Diabetes C, Complications Trial Research G. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968.

    Article  Google Scholar 

  108. The Diabetes C, Complications Trial Research G. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes. 1997;46(11):1829.

    Article  Google Scholar 

  109. Hietala K, Forsblom C, Summanen P, Groop P-H. Heritability of proliferative diabetic retinopathy. Diabetes. 2008;57(8):2176.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Rema M, Saravanan G, Deepa R, Mohan V. Familial clustering of diabetic retinopathy in south Indian type 2 diabetic patients. Diabet Med. 2002;19(11):910–6.

    Article  CAS  PubMed  Google Scholar 

  111. Hallman DM, Huber JC, Gonzalez VH, Klein BEK, Klein R, Hanis CL. Familial aggregation of severity of diabetic retinopathy in Mexican Americans from Starr County. Texas Diabetes Care. 2005;28(5):1163–8.

    Article  PubMed  Google Scholar 

  112. Looker HC, Nelson RG, Chew E, Klein R, Klein BEK, Knowler WC, et al. Genome-wide linkage analyses to identify loci for diabetic retinopathy. Diabetes. 2007;56(4):1160.

    Article  CAS  PubMed  Google Scholar 

  113. Leslie RD, Pyke DA. Diabetic retinopathy in identical twins. Diabetes. 1982;31(1):19.

    Article  CAS  PubMed  Google Scholar 

  114. Arar NH, Freedman BI, Adler SG, Iyengar SK, Chew EY, Davis MD, et al. Heritability of the severity of diabetic retinopathy: the FIND-eye study. Invest Ophthalmol Vis Sci. 2008;49(9):3839–45.

    Article  PubMed  Google Scholar 

  115. Abhary S, Hewitt AW, Burdon KP, Craig JE. A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes. 2009;58(9):2137–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Zhao S, Li T, Zheng B, Zheng Z. Nitric oxide synthase 3 (NOS3) 4b/a, T-786C and G894T polymorphisms in association with diabetic retinopathy susceptibility: a meta-analysis. Ophthalmic Genet. 2012;33(4):200–7.

    Article  CAS  PubMed  Google Scholar 

  117. Fu Y-P, Hallman DM, Gonzalez VH, Klein BEK, Klein R, Hayes MG, et al. Identification of diabetic retinopathy genes through a genome-wide association study among Mexican-Americans from Starr County. Texas J Ophthalmol. 2010;2010:861291.

    PubMed  Google Scholar 

  118. Grassi MA, Tikhomirov A, Ramalingam S, Below JE, Cox NJ, Nicolae DL. Genome-wide meta-analysis for severe diabetic retinopathy. Hum Mol Genet. 2011;20(12):2472–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Huang Y-C, Lin J-M, Lin H-J, Chen C-C, Chen S-Y, Tsai C-H, et al. Genome-wide association study of diabetic retinopathy in a Taiwanese population. Ophthalmology. 2011;118(4):642–8.

    Article  PubMed  Google Scholar 

  120. Sheu WHH, Kuo JZ, Lee IT, Hung Y-J, Lee W-J, Tsai H-Y, et al. Genome-wide association study in a Chinese population with diabetic retinopathy. Hum Mol Genet. 2013;22(15):3165–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Lin HJ, Huang YC, Lin JM, Wu JY, Chen LA, Tsai FJ. Association of genes on chromosome 6, GRIK2, TMEM217 and TMEM63B (linked to MRPL14) with diabetic retinopathy. Ophthalmologica. 2013;229(1):54–60.

    Article  PubMed  Google Scholar 

  122. Awata T, Yamashita H, Kurihara S, Morita-Ohkubo T, Miyashita Y, Katayama S, et al. A genome-wide association study for diabetic retinopathy in a Japanese population: potential association with a long intergenic non-coding RNA. PLoS One. 2014;9(11):e111715.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Burdon KP, Fogarty RD, Shen W, Abhary S, Kaidonis G, Appukuttan B, et al. Genome-wide association study for sight-threatening diabetic retinopathy reveals association with genetic variation near the GRB2 gene. Diabetologia. 2015;58(10):2288–97.

    Article  CAS  PubMed  Google Scholar 

  124. Graham PS, Kaidonis G, Abhary S, Gillies MC, Daniell M, Essex RW, et al. Genome-wide association studies for diabetic macular edema and proliferative diabetic retinopathy. BMC Med Genet. 2018;19(1):71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Pollack S, Igo RP, Jensen RA, Christiansen M, Li X, Cheng C-Y, et al. Multiethnic genome-wide association study of diabetic retinopathy using liability threshold modeling of duration of diabetes and glycemic control. Diabetes. 2019;68(2):441–56.

    Article  CAS  PubMed  Google Scholar 

  126. Meng W, Shah KP, Pollack S, Toppila I, Hebert HL, McCarthy MI, et al. A genome-wide association study suggests new evidence for an association of the NADPH oxidase 4 (NOX4) gene with severe diabetic retinopathy in type 2 diabetes. Acta Ophthalmol. 2018;96(7):e811–e9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. The Human Protein Atlas. 2019; [cited 2019]. Available from: https://www.proteinatlas.org/ENSG00000143748-NVL/tissue#top.

  128. Wang H, Yang Z, Jiang Y, Hartnett ME. Endothelial NADPH oxidase 4 mediates vascular endothelial growth factor receptor 2-induced intravitreal neovascularization in a rat model of retinopathy of prematurity. Mol Vis. 2014;20:231–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  129. Li J, Wang JJ, Zhang SX. NADPH oxidase 4-derived H2O2 promotes aberrant retinal neovascularization via activation of VEGF receptor 2 pathway in oxygen-induced retinopathy. J Diabetes Res. 2015;2015:963289.

    PubMed  PubMed Central  Google Scholar 

  130. Li J, Wang JJ, Yu Q, Chen K, Mahadev K, Zhang SX. Inhibition of reactive oxygen species by lovastatin downregulates vascular endothelial growth factor expression and ameliorates blood-retinal barrier breakdown in db/db mice: role of NADPH oxidase 4. Diabetes. 2010;59(6):1528–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA

    Weilin Chan

  2. Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA

    Lucia Sobrin

Authors
  1. Weilin Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lucia Sobrin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lucia Sobrin .

Editor information

Editors and Affiliations

  1. Casey Eye Institute, Oregon Health & Science, Portland, OR, USA

    Daniel M. Albert

  2. Department of Ophthalmology, Massachusetts Eye and Ear, Massachusetts General Hospital, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Joan W. Miller

  3. Department of Ophthalmology, University of Illinois College of Medicine, University of Illinois at Chicago, Chicago, IL, USA

    Dimitri T. Azar

  4. Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA

    Lucy H. Young

Section Editor information

  1. Department of Ophthalmology, Retina Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA

    Ivana Kim

  2. Massachusetts Eye and Ear, Boston, USA

    Yoshihiro Yonekawa

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Chan, W., Sobrin, L. (2022). Epidemiology and Genetics of Diabetic Retinopathy. In: Albert, D.M., Miller, J.W., Azar, D.T., Young, L.H. (eds) Albert and Jakobiec's Principles and Practice of Ophthalmology. Springer, Cham. https://doi.org/10.1007/978-3-030-42634-7_35

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-42634-7_35

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-42633-0

  • Online ISBN: 978-3-030-42634-7

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation